Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL
February 10th 2017Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.
Read More
Upfront Ibrutinib Continues to Impress in CLL
February 3rd 2017At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.
Read More
Many Challenges Loom in Ensuring Validity and Utility of Diagnostic Tests
May 12th 2015While diagnostic tests play a critical role in physician decision making-particularly in oncology-questions remain regarding the clinical utility of some of these tests, as well as the validity of laboratory-developed tests.
Read More
USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History
June 11th 2014Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations.
Read More